title: Medication-taking behavior in hypertensive patients with a single-tablet, fixed-dose combination in Japan.
abstract: Non-persistence rate (defined as not remaining on treatment) in patients taking a renin angiotensin system inhibitor plus calcium channel blocker was studied in three integrated 12-weeks surveys by matching separate drug combination therapy (CT) and fixed-dose combination (FDC). We also investigated medication adherence measured by proportion of days covered by using a claims database. The non-persistence rate was significantly lower in FDC than CT (p = 0.0074). In the database study, the medication adherence was higher in FDC than CT for 3, 6, and 12 months (all p < 0.001). In conclusion, use of single-tablet FDC antihypertensive therapy was associated with better medication-taking behavior.
authors.affiliation: a Keio University Health Center , Kanagawa , Japan .
authors.forename: Ikuo
authors.initials: I
authors.lastname: Saito
authors.affiliation: b The Life Planning Center Foundation , Tokyo , Japan .
authors.forename: Toshio
authors.initials: T
authors.lastname: Kushiro
authors.affiliation: c Daiichi Sankyo Co., Ltd , Tokyo , Japan , and.
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Matsushita
authors.affiliation: c Daiichi Sankyo Co., Ltd , Tokyo , Japan , and.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Sato
authors.affiliation: c Daiichi Sankyo Co., Ltd , Tokyo , Japan , and.
authors.forename: Kei
authors.initials: K
authors.lastname: Sagawa
authors.affiliation: c Daiichi Sankyo Co., Ltd , Tokyo , Japan , and.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Tanaka
authors.affiliation: c Daiichi Sankyo Co., Ltd , Tokyo , Japan , and.
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Tanigawa
authors.affiliation: d Daiichi Sankyo RD Novare Co., Ltd , Tokyo , Japan.
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Okutani
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001383:Azetidinecarboxylic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015331:Cohort Studies; D004095:Dihydropyridines / Q000627:therapeutic use*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007093:Imidazoles / Q000627:therapeutic use*; D007564:Japan; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011795:Surveys and Questionnaires; D013607:Tablets; D013777:Tetrazoles / Q000627:therapeutic use*; D016903:Drug Monitoring
chemical_list: D000959:Antihypertensive Agents; D004095:Dihydropyridines; D004338:Drug Combinations; D007093:Imidazoles; D013607:Tablets; D013777:Tetrazoles; D001383:Azetidinecarboxylic Acid; C437965:olmesartan; C061679:azelnidipine
keywords: Azelnidipine; Rezaltas; fixed-dose combination; medication-taking behavior; olmesartan